Related Experiment Video
Updated: May 20, 2026
02:28
Measuring Psoriasis Severity at Home
Published on: March 1, 2024
Etanercept in psoriatic arthritis
Antonio Spadaro1, Ennio Lubrano, Nicola Ferrara
1Dipartimento di Medicina Interna e Specialità Mediche, UOC di Reumatologia, Sapienza Università di Roma, Rome, Italy. a.spadaro.reuma@virgilio.it
The Journal of Rheumatology. Supplement
|July 4, 2012
Summary
Etanercept (ETN) effectively treats psoriatic arthritis (PsA), inhibiting radiographic progression and offering a favorable risk/benefit profile. Switching to other TNF-α blockers may benefit patients experiencing treatment failure.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Psoriatic arthritis (PsA) is a chronic inflammatory condition.
- Tumor necrosis factor-alpha (TNF-α) inhibitors are a key treatment modality for PsA.
Purpose of the Study:
- To provide an update on the use of etanercept (ETN) in managing psoriatic arthritis (PsA).
- To analyze ETN's efficacy, safety, optimal use, and economic impact in PsA patients.
Main Methods:
- Systematic review of randomized placebo-controlled trials and observational studies.
- Analysis of clinical efficacy, radiographic progression (modified total Sharp score), safety, and pharmacoeconomic data.
Main Results:
- Etanercept (ETN) demonstrated efficacy in PsA, inhibiting radiographic progression over 1-2 years.
- ETN (50 mg/weekly) can be used as monotherapy or with disease-modifying antirheumatic drugs (DMARDs).
- Short-term and long-term safety profiles are favorable, though some patients discontinue due to inefficacy or tolerability.
Conclusions:
- Etanercept (ETN) is an effective treatment for psoriatic arthritis (PsA) with a favorable safety profile.
- Switching to alternative TNF-α blockers may be beneficial for patients with treatment failure.
- ETN offers favorable pharmacoeconomic considerations in PsA management.
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:24T Cell Types and Functions
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...